Completed PHASE1 INTERVENTIONAL 3-arm
NCT06586671
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
An Open-Label, Two-Part, Two-Period Crossover Study to Determine Bioequivalence Between Nemtabrutinib FFP and FMF2 Formulations & FMF1 and FMF2 Formulations at 65 mg Single Dose in Healthy Male Participants
Sponsor: Merck Sharp & Dohme LLC
Conditions
Hematological Malignancy
Interventions
Nemtabrutinib
Updated 1 time since 2024 Last updated: Sep 6, 2024 Started: Aug 28, 2023 Primary completion: Nov 13, 2023 Completion: Nov 13, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Hematological Malignancy and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 1 recorded version since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Completed — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .